This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Soft On-Premise Sales to Mar Molson Coors' (TAP) Q2 Earnings
by Zacks Equity Research
Molson Coors' (TAP) second-quarter 2020 results are likely to reflect significant impacts from the closure of on-premise sales channels in almost all markets and other headwinds on the global economy.
Boston Beer (SAM) Stock Up on Q2 Earnings Beat, Sales Up Y/Y
by Zacks Equity Research
Boston Beer's (SAM) Q2 results gain from solid depletion growth along with strength in Truly Hard Seltzer and Twisted Tea as well as the Dogfish Head brands.
Factors Likely to Decide Archer Daniels' (ADM) Q2 Earnings
by Zacks Equity Research
Soft results across the Carbohydrate Solutions, and Ag Services and Oilseeds segments might show on Archer Daniels' (ADM) second-quarter 2020 results.
Clorox (CLX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Clorox (CLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Soap & Cleaning Materials Industry Outlook Bubbling With Optimism
by Rajani Lohia
Escalated demand for hand sanitizers, toilet paper, surface cleaners, disinfecting wipes and other household cleansing essentials are likely to aid Soap & Cleaning Materials players in the near term.
Kimberly-Clark (KMB) Q2 Earnings & Sales Top Estimates
by Zacks Equity Research
Kimberly-Clark (KMB) generates robust cost savings in second-quarter 2020. Also, the company witnesses strong demand in the Consumer Tissue segment amid the coronavirus outbreak.
Clorox (CLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $227.55, moving +0.36% from the previous trading session.
Here's How Mondelez (MDLZ) Looks Ahead of Q2 Earnings
by Zacks Equity Research
Impacts of higher customer service, labor and logistics costs are likely to get reflected in Mondelez's (MDLZ) second-quarter 2020 performance.
3 Reasons Why Growth Investors Shouldn't Overlook Clorox (CLX)
by Zacks Equity Research
Clorox (CLX) could produce exceptional returns because of its solid growth attributes.
Here's How Kimberly-Clark (KMB) Looks Ahead of Q2 Earnings
by Zacks Equity Research
Increased demand owing to consumer stockpiling trends amid the coronavirus outbreak is likely to get reflected in Kimberly-Clark's (KMB) second-quarter 2020 performance.
Factors to Decide the Fate of Coca-Cola (KO) in Q2 Earnings
by Zacks Equity Research
Coca-Cola's (KO) Q2 results are likely to reflect the impacts of declines in away-from-home channels and adverse currency. Growth in e-commerce is likely to have party cushioned its performance.
The Zacks Analyst Blog Highlights: Nu Skin Enterprises, Clorox, B&G Foods, Nomad Foods and Kellogg
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nu Skin Enterprises, Clorox, B&G Foods, Nomad Foods and Kellogg
Boston Beer (SAM) to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Boston Beer's (SAM) Q2 results are likely to reflect continued gains from strength in depletions and shipments. Soft on-premise demand and higher costs are expected to have marred its performance.
Clorox (CLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $227.91, moving +1.07% from the previous trading session.
Clorox (CLX) Is Up 3.42% in One Week: What You Should Know
by Zacks Equity Research
Does Clorox (CLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Consumer Staple Stocks to Buy With Earnings Beat Potential
by Vrishali Bagree
We have picked five consumer staple stocks, which are likely to report earnings beat this season owing to the burgeoning demand amid the pandemic-led increased at-home consumption.
Is The Clorox (CLX) Outperforming Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (CLX) Outperforming Other Consumer Staples Stocks This Year?
Here's Why Church & Dwight (CHD) Appears to be Sparkling
by Zacks Equity Research
Church & Dwight (CHD) has been gaining from burgeoning demand amid the pandemic. Also, the company's focus on innovation and buyouts has been aiding.
Why Colgate Stock Should Remain in Investors' Portfolio
by Zacks Equity Research
Colgate (CL) has been one of the beneficiaries of the rise in demand for everyday essentials amid the pandemic.
Zacks.com featured highlights include: T. Rowe Price, The Clorox Company, Lockheed Martin, Xilinx and The Sherwin-Williams Company
by Zacks Equity Research
Zacks.com featured highlights include: T. Rowe Price, The Clorox Company, Lockheed Martin, Xilinx and The Sherwin-Williams Company
7 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Factors to Decide the Fate of PepsiCo (PEP) in Q2 Earnings
by Zacks Equity Research
PepsiCo's (PEP) organic revenues for the second quarter are expected to have been marred by uncertainties related to the coronavirus outbreak and higher costs, offset by enhanced digital presence.
Clorox (CLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed at $229.50 in the latest trading session, marking a +1.74% move from the prior day.
Clorox (CLX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Clorox (CLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why the Earnings Surprise Streak Could Continue for Clorox (CLX)
by Zacks Equity Research
Clorox (CLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.